Table 3.
Summary of number of patients with TEAEs and CTCAE severity grade by study part and study treatment relatedness
| Study part | TEAEs | Related to study treatments | ||
|---|---|---|---|---|
| ≥1 TEAE n (%) |
≥1 Grade 3/4 n (%) |
≥1 TEAE n (%) |
≥1 Grade 3/4 n (%) |
|
| Part A (N = 39) | 37 (95) | 24 (62) | 10 (26) | 3 (8) |
| Part B (N = 26) | 26 (100) | 22 (85) | 15 (58) | 8 (31) |
| Part C (N = 14) | 14 (100) | 7 (50) | 3 (21) | 2 (14) |
| Total (N = 79) | 77 (97) | 53 (67) | 28 (35) | 13 (16) |
Study treatment relatedness in Part B is to either LY2157299, lomustine or both
CTCAE common terminology criteria for adverse events, TEAEs treatment-emergent adverse events